SYSTEMIC LIGHT CHAIN AMYLOIDOSIS
Clinical trials for SYSTEMIC LIGHT CHAIN AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC LIGHT CHAIN AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for SYSTEMIC LIGHT CHAIN AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare amyloidosis: drug targets Hard-to-Treat cases
Disease control Recruiting nowThis study tests a new drug called TQB2934 for people with systemic light chain amyloidosis, a rare disease where abnormal proteins build up in organs. The trial enrolls 70 adults who have already tried standard treatments. The goal is to see if the drug can improve blood markers…
Matched conditions: SYSTEMIC LIGHT CHAIN AMYLOIDOSIS
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 06:06 UTC
-
New antibody therapy shows promise for rare amyloidosis
Disease control Recruiting nowThis study tests a new drug called CM336, a type of antibody that targets both BCMA and CD3 proteins, in people newly diagnosed with AL amyloidosis. The goal is to see if a low dose can improve blood markers of the disease and to check for side effects. About 21 adults will take …
Matched conditions: SYSTEMIC LIGHT CHAIN AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 17, 2026 05:51 UTC